| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Short seller challenges Praxis' Phase 3 ulixacaltamide data, alleging major flaws that could undermine FDA approval and the...
https://culperresearch.com/wp-content/uploads/2025/11/Culper_PRAX_11-20-2025.pdf
BTIG analyst Kambiz Yazdi initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and announces Pric...
HC Wainwright & Co. analyst Douglas Tsao maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the pri...
Wedbush analyst Laura Chico maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Underperform and raises the price targe...
Praxis Precision Medicine (NASDAQ:PRAX) reported quarterly losses of $(3.36) per share which beat the analyst consensus estimat...
Comprehensive meeting with FDA conducted in Q3 in conjunction with Breakthrough Therapy DesignationKey aspects of a potential N...
Wedbush analyst Daniel Ives maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Underperform and raises the price targe...